An Eight-Gene Metabolic Prognostic Signature in Head and Neck Squamous Cell Carcinoma: Cross-Cohort Evaluation, Single-Cell Analysis, and Preliminary Functional Evaluation of PYGL and G6PD
Journal of Cancer · 2026-10-12 · 17 (11) · 1895-1914
DOI: 10.7150/jca.134402 ↗At a glance
Journal article in Journal of Cancer, published on 2026-10-12. Written by Wanyi Kou and 12 co-authors. Institution: Department of Otolaryngology-Head and Neck Surgery, Shaanxi Provincial Key Laboratory for Precision Diagnosis and Treatment of Otorhinolaryngology, T…. Cited 1 times so far (Crossref). The full text is freely available in PubMed Central.
Abstract (original language)
Background
Head and neck squamous cell carcinoma (HNSCC) is the most prevalent pathological subtype of head and neck malignancies. Although metabolic reprogramming contributes to malignant progression and adaptation within the tumor microenvironment in HNSCC, its biological and prognostic implications remain incompletely understood.
Objective
To develop and evaluate a metabolism-related prognostic score for head and neck squamous cell carcinoma (HNSCC) across multiple cohorts, identify its cellular sources at single-cell resolution, and perform preliminary in vitro functional evaluation of PYGL and G6PD.
Methods
Metabolism-related differentially expressed genes were screened in The Cancer Genome Atlas Head and Neck Squamous Cell Carcinoma cohort (TCGA-HNSC). A total of 506 patients with survival data were divided into a training set (n = 355) and an internal test set (n = 151) at a 7:3 ratio. Training-only repeated nested cross-validation benchmarked 126 algorithmic configurations. Survival-SVM had the highest mean out-of-fold C-index, whereas an eight-gene LASSO + StepCox model was retained for interpretability and cross-cohort transportability. External cohort evaluation of overall survival (OS) was performed in GSE65858 (n = 270), while GSE117973 (n = 77), which used disease-specific survival (DSS), was treated as an exploratory cohort. By integrating 54,163 single cells from the GSE150321 and GSE172577 datasets, analyses, including inferCNV, 12 predefined metabolic modules, CellChat, and scTenifoldKnk, were conducted to investigate the cellular origins of the risk score and candidate regulatory networks; additionally, PYGL- and G6PD-targeting siRNAs were evaluated for their effects on target protein expression and wound closure in vitro.
Results
We developed a metabolic prognostic model that included HPRT1, ADA, PYGL, P4HA1, LDHA, G6PD, NT5E, and FTH1. The concordance indices (C-indices) were 0.638 in the TCGA training set, 0.651 in the internal test set, and 0.604 in GSE65858. In a complete-case clinical cohort of 473 TCGA patients, a model combining the risk score with age, sex, and T, N, and M categories achieved C-indices of 0.693 in TCGA and 0.677 in GSE65858. The corresponding 3-year areas under the receiver operating characteristic curve (AUCs) were 0.735 and 0.700. Single-cell analysis showed that the eight genes were distributed across malignant epithelial, proliferating, immune, endothelial, and stromal populations. The 16,240 copy number variation-high (CNV-high) epithelial cells had higher eight-gene scores and higher transcriptional scores for glycogen metabolism, the pentose phosphate pathway, glycolysis, and redox-related programs. Small interfering RNA (siRNA)-mediated silencing of G6PD or PYGL reduced relative wound closure at 12 h in TU686 and SCC25 cells.
Conclusion
The eight-gene metabolic score provided moderate and cohort-dependent prognostic discrimination in the TCGA internal test set and GSE65858. Its bulk transcriptomic signal arose from several cell populations. Silencing PYGL or G6PD reduced target protein expression and wound closure. These findings provide preliminary in vitro evidence linking both genes to a migratory phenotype in HNSCC.
Subjects
Author keywords
Authors and institutions
- Department of Otolaryngology-Head and Neck Surgery, Shaanxi Provincial Key Laboratory for Precision Diagnosis and Treatment of Otorhinolaryngology, The Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an 7100…
- Department of Otolaryngology-Head and Neck Surgery, Luoyang Central Hospital Affiliated to Zhengzhou University.
Cite
APA
Kou, W., Guo, R., Zhang, Y., Xu, C., Sha, W., Chen, Y., Lei, Y., Zhang, N., Liao, K., Liang, D., Zhang, Y., Wei, Z., & Wang, Z. (2026). An Eight-Gene Metabolic Prognostic Signature in Head and Neck Squamous Cell Carcinoma: Cross-Cohort Evaluation, Single-Cell Analysis, and Preliminary Functional Evaluation of PYGL and G6PD. Journal of Cancer, 17(11), 1895-1914. https://doi.org/10.7150/jca.134402
Vancouver
Kou W, Guo R, Zhang Y, Xu C, Sha W, Chen Y, et al. An Eight-Gene Metabolic Prognostic Signature in Head and Neck Squamous Cell Carcinoma: Cross-Cohort Evaluation, Single-Cell Analysis, and Preliminary Functional Evaluation of PYGL and G6PD. Journal of Cancer. 2026;17(11):1895-1914. doi:10.7150/jca.134402
BibTeX
@article{Kou2026,
author = {Kou, Wanyi and Guo, Ruixin and Zhang, Yifan and Xu, Chensi and Sha, Wenqi and Chen, Yijie and Lei, Yuran and Zhang, Ningrui and Liao, Kun and Liang, Danni and Zhang, Yang and Wei, Zhenxing and Wang, Zhenghui},
title = {An Eight-Gene Metabolic Prognostic Signature in Head and Neck Squamous Cell Carcinoma: Cross-Cohort Evaluation, Single-Cell Analysis, and Preliminary Functional Evaluation of PYGL and G6PD},
journal = {Journal of Cancer},
year = {2026},
volume = {17},
number = {11},
pages = {1895--1914},
doi = {10.7150/jca.134402}
}
EUVIMED